Analysts Issue Forecasts for TLSI FY2026 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for TriSalus Life Sciences in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings per share of ($0.36) for the year. The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The company had revenue of $9.17 million for the quarter, compared to the consensus estimate of $9.04 million. During the same quarter last year, the company posted ($0.60) earnings per share.

A number of other equities analysts have also commented on the company. Lake Street Capital assumed coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a "buy" rating and a $10.00 price objective on the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, TriSalus Life Sciences presently has an average rating of "Buy" and a consensus price target of $10.75.

TriSalus Life Sciences Stock Down 0.2%

Shares of NASDAQ TLSI traded down $0.01 during trading on Tuesday, reaching $5.58. The company had a trading volume of 34,836 shares, compared to its average volume of 42,213. The stock has a market cap of $211.14 million, a P/E ratio of -2.24 and a beta of 0.47. The company's fifty day moving average price is $5.39 and its 200-day moving average price is $5.14. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $6.62.

Insider Transactions at TriSalus Life Sciences

In related news, insider Richard Marshak sold 6,597 shares of the stock in a transaction on Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the transaction, the insider now directly owns 69,101 shares of the company's stock, valued at $357,943.18. This represents a 8.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 16,125 shares of company stock valued at $83,528 in the last quarter. 27.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors have recently made changes to their positions in TLSI. Charles Schwab Investment Management Inc. bought a new stake in TriSalus Life Sciences in the 1st quarter valued at about $55,000. Renaissance Technologies LLC acquired a new stake in TriSalus Life Sciences in the fourth quarter valued at approximately $67,000. Connective Capital Management LLC bought a new stake in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $140,000. Northern Trust Corp raised its position in shares of TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after purchasing an additional 5,936 shares during the period. Finally, Goldman Sachs Group Inc. bought a new position in shares of TriSalus Life Sciences in the 1st quarter worth $187,000. Institutional investors and hedge funds own 2.58% of the company's stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.